Embusartan, formerly known as BAY 10-6734, is a potent, orally bioavailable angiotensin II receptor antagonist being developed by Bayer as an antihypertensive agent. The compound has potential for once daily administration with antihypertensive activity still present over a 24-h period. Embusartan was under preclinical development in Germany for the treatment of hypertension. References: Wang JM, Tan J, Leenen FH. Central nervous system blockade by peripheral administration of AT1 receptor blockers. J Cardiovasc Pharmacol. 2003 Apr;41(4):593-9. PubMed PMID: 12658061.

纯度：≥98%

CAS：156001-18-2